Ep. 84 – Leadership Amid Turmoil: Moonlake CEO Jorge Santos Da Silva
As CEO of a vintage 2021 biotech, Jorge Santos Da Silva has had his leadership mettle tested by a pandemic, rising interest rates, a bear market, and a tumultuous U.S. policy environment — all while building the case for Moonlake’s lead program to become a top therapy for hidradenitis suppurativa and, eventually, a “pipeline-in-a-product.”The key for Santos Da Silva as founder and CEO of Moonlake Immunotherapeutics is to dial down the noise and focus on the key choices in front of you. “Moonlake has always existed in times of turmoil,” Santos Da Silva told Executive Editor Jeff Cranmer on The BioCentury Show, citing the recent M&A drought, high interest rates and political turmoil. “Understanding the situation from a cool perspective, being able to explain that to your people first, and then try to explain that to the Street and place the company in the right moment so that you have all the game in front of you" is his recipe for success as a CEO in biotech. Moonlake’s sonelokimab is expected to enter Phase III testing this year for HS; it's one of the most advanced multispecifics in the clinic for inflammation and immunology diseases.View full story: https://www.biocentury.com/article/655903#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment00:00 - Introduction01:48 - Landscape for HS Therapies09:03 - Market Opportunity19:40 - Next Steps for Moonlake
--------
29:19
Ep. 83 – Europe’s Biotech Moment: Jérôme van Biervliet on Turning Uncertainty into Opportunity
Europe did not ask for this opportunity, says VIB’s Jérôme van Biervliet, but with FDA and the U.S. research funding situation headed into uncertain territory, it needs to use this moment to capitalize on its strengths in research, and address the shortcomings of its business and regulatory systems that have made it hard for biotech to fulfill its potential there. Van Biervliet is managing director of Flanders Institute for Biotechnology (VIB), a key player in the Belgian biotech landscape that has both a research arm and an investment unit. Ahead of BioCentury’s Bio€quity Europe conference in Bruges, which will discuss how Europe can meet the complexity of this moment, he talked to BioCentury Editor in Chief Simone Fishburn on The BioCentury Show about the landscape unfolding in Europe, as well as where he sees innovation headed.View full story: https://www.biocentury.com/article/655818#biotech #biopharma #pharma #LifeScience #ResearchFunding #EuropeanInnovation00:00 - Introduction02:03 - VIB’s Mission07:52 - Europe’s Funding Opportunity17:37 - Belgium’s Biotech Ecosystem25:27 - Nanobodies’ Potential
--------
31:54
Ep. 82 – Act Now or Fall Behind: Michelle Rozo on Biotech’s National Security Stakes
The U.S. will cede its preeminence in biotechnology to China within three years unless the government acts urgently, an independent commission chartered by Congress warns. “Our window to act is closing,” the National Security Commission on Emerging Biotechnology said in a newly released report. “We need a two-track strategy: make America innovate faster, and slow China down.” BioCentury Washington Editor Steve Usdin discusses the report's recommendations and warnings with the commission’s vice chair, Michelle Rozo, on The BioCentury Show.View full story: https://www.biocentury.com/article/655654#biotech #biopharma #pharma #lifescience #politics #policy #law 00:00 - Introduction03:56 - China Closing the Innovation Gap09:20 - Slowing China Down17:20 - Bolstering U.S. Biotech
--------
31:01
Ep. 81 - Data-Driven Growth: Immunocore CEO Bahija Jallal on Expanding TCR Therapies
On the latest episode of The BioCentury Show, Editor in Chief Simone Fishburn speaks with Bahija Jallal, CEO of Immunocore and the former president of Medimmune. While some biotechs are circumspect about gathering data during clinical trials that might not support the product in question, Jallal sees it as part of the obligation to patients and the field to learn as much as possible, as efficiently as possible. And that strategy has informed how the company will take its TCR technology into earlier lines of treatment and new indications.View full story: https://www.biocentury.com/article/655504#biopharma #pharma #biotech #lifescience #RandD #DrugDevelopment #CEO00:00 - Introduction04:18 - Getting a New Modality to Market17:15 - Infectious Pipeline22:04 - Autoimmune Pipeline27:24 - Leading in Challenging Times
--------
30:52
Ep. 80 - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs
Vertex’s approach to research, defined over a decade ago to beat the dismal odds of success in biotech, remains core to its strategy, even as the industry evolves and technologies expand. While that strategy, which EVP and CSO David Altshuler calls “serial innovation,” has seen the company launch eight drugs since 2011 and jump market cap tiers on the success of its cystic fibrosis portfolio, it’s now being tested in other areas as Vertex expands to pain, renal disease, Type I diabetes, and more. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Altshuler discussed the rising interest in causal biology and the role of AI, noting that the fundamentals of picking targets and programs have not changed.View full story: https://www.biocentury.com/article/655408#biotech #biopharma #pharma #lifescience#RandD #DrugDevelopment #AI00:00 - Introduction02:12 - Causal Biology08:48 - AI in R&D, at Vertex16:35 - Academia-Industry Interface22:00 - Cell Therapy for Diabetes25:35 - Gene Therapy for DMD
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
UK